Molecular crosstalk between trail and natural antioxidants in the treatment of cancer

British Journal of Pharmacology

Volumn 157, Issue 7, 2009, Pages 1186-1188

  Rushworth, Stuart A ^a   Micheau, Olivier ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Antioxidants; Apoptosis; Cell death; Flavonoid; P53; Puma; ROS; TRAIL; Tumour; Wogonin

Indexed keywords

3 INDOLEMETHANOL; AMG 655; ANTINEOPLASTIC AGENT; ANTIOXIDANT; APIGENIN; CASPASE 10; CASPASE 8; CS 1008; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; GENISTEIN; HISTONE H2AX; LBY 135; LEXATUMUMAB; MAPATUMUMAB; PROTEIN BAX; PROTEIN P53; PUMA PROTEIN; QUERCETIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RESVERATROL; SULFORAPHANE; UNCLASSIFIED DRUG; WOGONIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CELL DEATH; CLINICAL TRIAL; CYTOTOXICITY; DNA DAMAGE; DRUG BIOAVAILABILITY; DRUG MECHANISM; HUMAN; NOTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; DRUG SYNERGISM; FLAVANONES; HUMANS; PROTO-ONCOGENE PROTEINS; REACTIVE OXYGEN SPECIES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 70350336226     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00266.x     Document Type: Note

References (11)

1. Ashkenazi A, Holland P, Eckhardt SG (2008). Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 26: 3621-3630
2. Delmas D, Rébé C, Micheau O, Athias A, Gambert P, Grazide S et al. (2004). Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 23: 8979-8986
3. Ishibashi M, Ohtsuki T (2008). Studies on search for bioactive natural products targeting TRAIL signaling leading to tumor cell apoptosis. Med Res Rev 28: 688-714
4. Ivanov VN, Partridge MA, Johnson GE, Huang SX, Zhou H, Hei TK (2008). Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp Cell Res 314: 1163-1176
5. Lee D-H, Rhee JG, Lee YJ (2009) Reactive oxygen species up-regulate p53 and Puma; a possible mechanism for apoptosis during combined treatment with TRAIL and wogonin. Br J Pharmacol 157: 1189-1202
6. Merino D, Lalaoui N, Morizot A, Solary E, Micheau O (2007). TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets 11: 1299-1314
7. Meurette O, Fontaine A, Rebillard A, Le Moigne G, Lamy T, Lagadic-Gossmann D et al. (2006). Cytotoxicity of TRAIL/anticancer drug combinations in human normal cells. Ann N Y Acad Sci 1090: 209-216
8. Reuter S, Eifes S, Dicato M, Aggarwal BB, Diederich M (2008). Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol 76: 1340-1351
9. Solier S, Sordet O, Kohn KW, Pommier Y (2009). Death receptor-induced activation of the Chk2-and histone H2AX-associated DNA damage response pathways. Mol Cell Biol 29: 68-82
10. Taniguchi H, Yoshida T, Horinaka M, Yasuda T, Goda AE, Konishi M et al. (2008). Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells. Cancer Res 68: 8918-8927
11. Ye R, Goodarzi AA, Kurz EU, Saito S, Higashimoto Y, Lavin MF et al. (2004). The isoflavonoids genistein and quercetin activate different stress signaling pathways as shown by analysis of site-specific phos-phorylation of ATM, p53 and histone H2AX. DNA Repair (Amst) 3: 235-244